Literature DB >> 9864868

Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation.

L Hoekx1, W Jeuris, E Van Marck, J J Wyndaele.   

Abstract

Prostatic subclinical inflammation is associated with elevated serum prostate specific antigen (PSA) level when there is contact with and disruption of the glandular epithelium of the prostate. This aggressiveness of the inflammation was graded on a 4-point scale proposed by Irani (1). Patients with an elevated serum PSA level and no malignancy in their transrectal prostate biopsy, have a lower risk of biopsy missed prostate carcinoma when there is an inflammation with a high aggressiveness score. The density itself of the inflammatory cells in the prostatic tissue was not associated with the serum PSA level. We believe that both issues should be considered when interpreting a prostate biopsy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9864868

Source DB:  PubMed          Journal:  Acta Urol Belg        ISSN: 0001-7183


  8 in total

1.  Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy.

Authors:  Antonio B Porcaro; Giovanni Novella; Daniele Mattevi; Leonardo Bizzotto; Giovanni Cacciamani; Nicolò De Luyk; Irene Tamanini; Maria A Cerruto; Matteo Brunelli; Walter Artibani
Journal:  Curr Urol       Date:  2016-05-20

2.  Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Authors:  M H Umbehr; B Gurel; T J Murtola; S Sutcliffe; S B Peskoe; C M Tangen; P J Goodman; I M Thompson; S M Lippman; M S Lucia; H L Parnes; C G Drake; W G Nelson; A M De Marzo; E A Platz
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-05       Impact factor: 5.554

3.  Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

Authors:  Gianluigi Taverna; Giorgio Bozzini; Fabio Grizzi; Mauro Seveso; Alberto Mandressi; Luca Balzarini; Federica Mrakic; Pietro Bono; Oliviero De Franceco; NicolòMaria Buffi; Giovanni Lughezzani; Massimo Lazzeri; Paolo Casale; Giorgio Ferruccio Guazzoni
Journal:  World J Urol       Date:  2015-10-19       Impact factor: 4.226

4.  The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml.

Authors:  Ali Saribacak; Hasan Yilmaz; Seyfettin Ciftci; Murat Ustuner; Levend Ozkan; Tayyar Alp Ozkan; Ozdal Dillioglugil
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 5.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 6.  Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Authors:  Alexander Haese; Markus Graefen; Hartwig Huland; Hans Lilja
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 3.092

7.  Associations of Transitional Zone Volume with Intraprostatic Chronic Inflammation and Prostate Cancer Risk in Patients Undergoing a First Random Biopsy Set.

Authors:  Antonio B Porcaro; Daniele Mattevi; Giovanni Novella; Nicolò De Luyk; Paolo Corsi; Leonardo Bizzotto; Davide De Marchi; Marco Sebben; Alessandro Tafuri; Davide Inverardi; Tania Processali; Maria A Cerruto; Matteo Brunelli; Salvatore Siracusano; Walter Artibani
Journal:  Curr Urol       Date:  2017-12-30

8.  Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study.

Authors:  Antonio Benito Porcaro; Giovanni Novella; Matteo Balzarro; Guido Martignoni; Matteo Brunelli; Giovanni Cacciamani; Maria A Cerruto; Walter Artibani
Journal:  Asian J Urol       Date:  2015-09-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.